Kailera Therapeutics, Inc. (KLRA) Stock Overview
Explore Kailera Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Kailera Therapeutics, Inc. (KLRA)
Key Financials
Key Financials
Market Cap
1.6B
P/E Ratio
-6.80
EPS (TTM)
$-2.25
ROE
-0.55%
KLRA Stock Analysis & Investment Overview (NASDAQ)
Our AI-powered analysis of Kailera Therapeutics, Inc. (NASDAQ: KLRA) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of C+, Kailera Therapeutics, Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.
The current technical analysis of KLRA on the NASDAQ shows an RSI of 26.26, suggesting the stock is in a an oversold condition. Our forecasting models predict a 12-month price target of $22.70 for the NASDAQ listing.
Key metrics behind Kailera Therapeutics, Inc.'s NASDAQ-traded stock include a P/E ratio of -6.80 and a market capitalization of 1.6B. Combined with our AI analysis, these give both institutional and retail investors a clear view of KLRA on the NASDAQ.